deltatrials
Completed NA NCT01578447

Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda

Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda

Sponsor: Bill and Melinda Gates Foundation

Conditions Acceptability of Different Contraceptive Injection Types
Interventions DepoSubQ Provera 104 in Uniject Intramuscular DMPA
Updated 5 times since 2017 Last updated: Sep 16, 2014 Started: Apr 30, 2012 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This NA trial investigates Acceptability of Different Contraceptive Injection Types and is currently completed. Bill and Melinda Gates Foundation leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bill and Melinda Gates Foundation
  • Johns Hopkins Bloomberg School of Public Health
  • Rakai Health Sciences Program
  • Society of Family Planning
Data source: Johns Hopkins Bloomberg School of Public Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Kalisizo, Uganda